Citigroup assumed coverage on shares of Repligen (NASDAQ:RGEN) in a research report released on Friday morning. The brokerage issued a buy rating and a $45.00 price objective on the biotechnology company’s stock.

Other research analysts have also issued reports about the company. TheStreet raised Repligen from a c+ rating to a b- rating in a report on Friday, August 11th. Zacks Investment Research raised Repligen from a hold rating to a buy rating and set a $43.00 target price on the stock in a report on Thursday, October 5th. CL King started coverage on Repligen in a report on Monday, November 13th. They set a buy rating and a $41.00 target price on the stock. Jefferies Group reaffirmed a hold rating and set a $40.00 target price on shares of Repligen in a report on Thursday, September 14th. Finally, J P Morgan Chase & Co started coverage on Repligen in a report on Tuesday. They set an overweight rating and a $42.00 target price on the stock. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has an average rating of Buy and an average target price of $44.38.

Shares of Repligen (NASDAQ RGEN) traded up $0.98 during mid-day trading on Friday, hitting $35.56. The stock had a trading volume of 265,632 shares, compared to its average volume of 353,978. The firm has a market capitalization of $1,506.49, a price-to-earnings ratio of 59.62, a PEG ratio of 2.26 and a beta of 1.04. Repligen has a fifty-two week low of $28.48 and a fifty-two week high of $46.81.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.04. The business had revenue of $36.58 million for the quarter, compared to analyst estimates of $35.69 million. Repligen had a return on equity of 7.57% and a net margin of 16.93%. The company’s revenue was up 48.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.08 earnings per share. research analysts predict that Repligen will post 0.61 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. grew its holdings in Repligen by 3.7% during the second quarter. BlackRock Inc. now owns 4,834,853 shares of the biotechnology company’s stock worth $200,355,000 after acquiring an additional 170,551 shares during the period. TimesSquare Capital Management LLC grew its holdings in Repligen by 19.8% during the second quarter. TimesSquare Capital Management LLC now owns 2,361,270 shares of the biotechnology company’s stock worth $97,851,000 after acquiring an additional 390,545 shares during the period. Vanguard Group Inc. grew its holdings in Repligen by 9.7% during the second quarter. Vanguard Group Inc. now owns 1,984,393 shares of the biotechnology company’s stock worth $82,233,000 after acquiring an additional 175,191 shares during the period. Conestoga Capital Advisors LLC grew its holdings in Repligen by 12.5% in the third quarter. Conestoga Capital Advisors LLC now owns 1,453,232 shares of the biotechnology company’s stock valued at $55,688,000 after purchasing an additional 161,427 shares during the period. Finally, FMR LLC grew its holdings in Repligen by 6.2% in the second quarter. FMR LLC now owns 1,334,090 shares of the biotechnology company’s stock valued at $55,285,000 after purchasing an additional 78,060 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This article was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.watchlistnews.com/repligen-rgen-coverage-initiated-by-analysts-at-citigroup/1754476.html.

Repligen Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.